|Bid||89.00 x 900|
|Ask||0.00 x 900|
|Day's range||93.50 - 96.36|
|52-week range||35.25 - 123.31|
|Beta (5Y monthly)||1.89|
|PE ratio (TTM)||N/A|
|Earnings date||27 Oct 2020 - 02 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||115.43|
EXAS earnings call for the period ending June 30, 2020.
Exact Sciences' (EXAS) legacy screening business sees a decline in revenues in Q2 earnings.
Exact Sciences (NASDAQ: EXAS) hasn't fired up investors so far in 2020 like it did last year. The good news is that Exact Sciences' management team said that there were signs of improvement in the quarterly conference call in May. Here are the highlights from Exact Sciences' Q2 update.